Type 1 and Type 2 Diabetes and the Brain

2019 ◽  
pp. 116-136
Author(s):  
Olga Neyman ◽  
Tamara Hershey
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Peripheral Neuropathy ◽  
Side Effects ◽  
Current Knowledge ◽  
The World ◽  
The Brain

This chapter focuses on the neurocognitive effects of diabetes mellitus, particularly type 1 and type 2 diabetes. Although many of the side effects of diabetes—such as retinopathy, nephropathy, and peripheral neuropathy—are well known, the consequences on cognition have received comparatively little attention. These consequences will become more important as the rate of diabetes continues to rise at a staggering rate and millions of people are affected throughout the world. This chapter provides an overview of the current knowledge on how diabetes mellitus affects cognitive function, emphasizing the role of hypo- and hyperglycemia, while placing it in the context of diabetes as a whole.

Diabetic neuropathy: Epidemiological, pathogenetic, and clinical aspects with special emphasis on type 2 diabetes mellitus

1983 ◽  
Vol 104 (4_Suppl) ◽  
pp. S89-S94
Author(s):  
E. Matikainen ◽  
J. Juntunen
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Peripheral Neuropathy ◽  
Diabetic Control ◽  
Clinical Aspects ◽  
Type 2 Diabetics ◽  
Insulin Dependent

ABSTRACT. Peripheral neuropathy is a frequent complication of diabetes mellitus. Alterations of the peripheral nervous system in diabetics have been studied in numerous investigations. There are many factors known to participate in the development of this complication, e.g. the age of the patient, duration of the diabetes, quality of the diabetic control etc. The role of different types of diabetes in development of neuropathy is still largely unclear since investigations on this aspect are few. It seems, however, that peripheral neuropathy in type 2 (non-insulin dependent) diabetes is common but often mild. The differential diagnosis of the peripheral neuropathy in type 2 diabetics is more difficult than in type 1 (insulin dependent) diabetics, since these patients tend to be older and also may have other concomitant disorders. In this paper the clinical features and pathogenetic mechanisms of neuropathy in type 2 diabetes are briefly discussed.

scholarly journals The protean role of haptoglobin and haptoglobin genotypes on vascular complications in diabetes mellitus

2018 ◽  
Vol 25 (14) ◽  
pp. 1502-1519 ◽  
Author(s):  
Rinkoo Dalan ◽  
Goh Liuh Ling
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Vitamin E ◽  
Clinical Studies ◽  
Vascular Complications ◽  
Cardiovascular Complications ◽  
Diabetes Patients

Introduction and background Haptoglobin (Hp) is considered to be an antioxidant and protective against cardiovascular complications. Polymorphisms in the Hp gene interact with diabetes mellitus to affect the risk of vascular complications. Methods We review the updated literature about the protean role of Hp and Hp genotypes spanning genomics, molecular, translational and clinical studies. We searched Pubmed, SCOPUS and Google Scholar for all articles using the keywords: haptoglobin and/or haptoglobin polymorphism and diabetes. We review the diverse Hp genotypes, phenotypes and the impact on diabetes complications, including lessons from animal models and in vitro models. We describe the clinical studies on the associations of Hp genotypes with vascular complications in type 1 and type 2 diabetes comprehensively. We review the studies looking at vitamin E supplementation in a personalized manner in Hp2-2 diabetes individuals. Results and conclusion Hp genotypes have evolved as a result of deletions in the traditional Hp genes. The Hp genotypes have been associated with microvascular and macrovascular complications in type 1 diabetes mellitus but the association in type 2 diabetes is more consistent with cardiovascular complications. A preferential benefit of vitamin E and other antioxidants in the Hp2-2 genotype for cardiovascular complications in type 2 diabetes has been seen presumably secondary to interaction with high-density lipoprotein function. Hence, the Hp genotype can be used to personalize antioxidant therapeutics in diabetes patients. These results need to be corroborated in large, global, pragmatic, prospective, cardiovascular outcome trials in type 2 diabetes patients.

scholarly journals O-GlcNAcylation, oxidation and CaMKII contribute to atrial fibrillation in type 1 and type 2 diabetes by distinct mechanisms

2020 ◽  
Author(s):  
Olurotimi O. Mesubi ◽  
Adam G. Rokita ◽  
Neha Abrol ◽  
Yuejin Wu ◽  
Biyi Chen ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Atrial Fibrillation ◽  
Type 2 Diabetes ◽  
Calmodulin Kinase ◽  
Elevated Protein ◽  
Intracellular Ca ◽  
Genetic Mouse Models

AbstractDiabetes mellitus and atrial fibrillation (AF) are major unsolved public health problems, and diabetes is an independent risk factor for AF in patients. However, the mechanism(s) underlying this clinical association is unknown. Elevated protein O-GlcNAcylation (OGN) and reactive oxygen species (ROS) are increased in diabetic hearts, and calmodulin kinase II (CaMKII) is a proarrhythmic signal that may be activated by OGN (OGN-CaMKII) and ROS (ox-CaMKII). We induced type 1 (T1D) and type 2 diabetes (T2D) in a portfolio of genetic mouse models capable of dissecting the role of OGN and ROS at CaMKII and the type 2 ryanodine receptor (RyR2), an intracellular Ca2+ channel implicated as an important downstream mechanism of CaMKII- mediated arrhythmias. Here we show that T1D and T2D significantly increased AF, similar to observations in patients, and this increase required CaMKII. While T1D and T2D both require ox-CaMKII to increase AF, they respond differently to loss of OGN-CaMKII or OGN inhibition. Collectively, our data affirm CaMKII as a critical proarrhythmic signal in diabetic AF, and suggest ROS primarily promotes AF by ox-CaMKII, while OGN promotes AF by diverse mechanisms and targets, including CaMKII and RyR2. The proarrhythmic consequences of OGN- and ox-CaMKII differ between T1D and T2D. These results provide new and unanticipated insights into the mechanisms for increased AF in diabetes mellitus, and suggest successful future therapies will need to be different for AF in T1D and T2D.

6. Appetite, fat, and obesity

2014 ◽  
pp. 74-87
Author(s):  
Martin Luck
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 1 Diabetes ◽  
The Body ◽  
Storage Process ◽  
Lifestyle Disease ◽  
Energy Shortage

‘Appetite, fat, and obesity’ considers the role of insulin in the body’s fat storage process. In the condition diabetes mellitus, the sugar level in the blood rises uncontrollably so the kidneys cannot stop it leaking into the urine. Type 1 diabetes is an autoimmune disease in which a person’s immune system attacks the insulin-secreting β-cells of the pancreas. The only effective treatment is to inject the missing insulin. Type 2 diabetes is considered more of a lifestyle disease. But what exactly is the connection between obesity and poorly regulated blood glucose? The body has more hormones capable of responding to energy shortage than to energy abundance, which may be why keeping control of body weight can be difficult. The hormones affecting appetite are also discussed.

Sign in / Sign up

Export Citation Format

Share Document